Results 31 to 40 of about 76,806 (261)
Advanced Science, EarlyView.This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma +10 more
wiley +1 more source
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Haematologica, 2018 Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li +21 more
doaj +1 more source
HIV ASSOCIATED LYMPHOMA – TWO CASE REPORT SERIES [PDF]
Romanian Journal of Infectious Diseases, 2016 Combined antiretroviral therapy significantly improved the prognosis and the life expectancy of HIV patients. Along with this, the profile of HIV associated malignant pathologies has changed. Among these, lymphoma, with a higher incidence than in general
Liana-Cătălina Gavriliu +1 more
doaj +1 more source
Advanced Science, EarlyView.Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu +13 more
wiley +1 more source
Haematologica, 2018 Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein +11 more
doaj +1 more source
Advanced Science, EarlyView.A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun +15 more
wiley +1 more source
Pediatric Clinics of North America, 1997 Pediatric lymphomas are the third most common group of malignancies in children and adolescents. Unlike lymphomas in adults, pediatric lymphomas are diffuse, aggressive neoplasms with a propensity for widespread dissemination. Intensification of conventional treatment approaches along with improvements in supportive care have resulted in dramatic ...
A, Shad, I, Magrath
openaire +2 more sources
Advanced Science, EarlyView.In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao +6 more
wiley +1 more source
The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma
High Yield Medical ReviewsChimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma.
Emaan Haque +4 more
doaj +1 more source
T-Cell/Histiocyte Rich Large B-Cell Lymphoma –A Case Series with Review of Literature [PDF]
National Journal of Laboratory Medicine, 2017 T-Cell/Histiocyte Rich Large B-Cell Lymphoma (THRLBCL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL). This entity differs from the classical DLBCL in the morphology as well as immunohistochemical expression of various CD markers.
Priavadhana Rajan Prasaad +1 more
doaj +1 more source